
Molecular Partners AG
- Jurisdiction
Switzerland - LEI
875500AXMLDAZ4D21744 - ISIN
CH0256379097 (MOLN.SW )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Read full profile
Stock price
Fundamentals
- Net revenue
€737.09K - Gross margin
18.8% - EBIT
-€68.02M - EBIT margin
-9,227.9% - Net income
-€70.14M - Net margin
-9,516.2%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
N/A | N/A |
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: March 7, 2025